| (Values in U.S. Thousands) | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 | Sep, 2020 |
| Sales | 20 | 150 | 350 | 480 | 0 |
| Sales Growth | -86.67% | -57.14% | -27.08% | unch | -100.00% |
| Net Income | -7,440 | -18,830 | -29,720 | -24,980 | -24,270 |
| Net Income Growth | +60.49% | +36.64% | -18.98% | -2.93% | -36.89% |
Hyperliquid Strategies Inc (PURR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J.